A novel adjuvant Ling Zhi-8 for cancer DNA vaccines.

Abstract

DNA vaccines have a wide range of applications, with several potential advantages compared to other vaccine technologies for diseases. No DNA vaccine has yet been licensed in humans; however, a lot of effort has been made to enhance their potential as human vaccines and therapeutics. Finding an effective adjuvant is a strategy to improve the efficacy of DNA vaccines. We recently identified a fungal immunomodulatory protein Ling Zhi-8 (LZ-8) with stimulatory activity on dendritic cells (DCs) that significantly increases the efficacy of a cancer DNA vaccine in a preclinical tumor model, suggesting that LZ-8 may be a good candidate adjuvant for vaccine development. Here we discuss the possibility for applying LZ-8 to a cancer DNA vaccine for humans.

• Authors: Ching-Liang Chu, Dz-Chi Chen, Chi-Chen Lin
• Journal: Human vaccines (Hum Vaccin) Vol. 7 Issue 11 Pg. 1161-4 (Nov 2011) ISSN: 1554-8619 [Electronic] United States
• PMID: 22048115 (Publication Type: Journal Article)

Chemical References

• Adjuvants, Immunologic
• Antibodies
• Cancer Vaccines
• Fungal Proteins
• Vaccines, DNA
• LZ-8 protein, Ganoderma lucidum

Topics

• Adjuvants, Immunologic
• Animals
• Antibodies (blood)
• Breast Neoplasms (immunology, therapy)
• Cancer Vaccines (immunology)
• Clinical Trials as Topic
• Dendritic Cells (immunology)
• Female
• Fungal Proteins (immunology)
• Humans
• Immunomodulation
• Mice
• Ovarian Neoplasms (immunology, therapy)
• T-Lymphocytes (immunology)
• Vaccines, DNA (immunology)